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PRIMED AND BOOSTED ANTI-BREAST CANCER TUMOR IMMUNITY AFTER
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT):
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AFTER PBSCT WITH ACTIVATED T CELLS (ATC)
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Innovative treatment strategies are needed for women with meta-
static breast cancer. In a phase I immunotherapy (IT) trial, infusions
of ATC armed with anti-CD3 x anti-Her2/neu bispecific antibody
(Her2Bi) induced specific cytotoxicity (SC) in the peripheral blood
lymphocytes (PBL) directed at SK-BR-3 breast cancer cells. Armed
ATC induced high levels of Th1 cytokines and IL-12 in the serum
of patients. After IT, we obtained memory T cells by leukopheresis,
expanded the T cells, and re-infused the T cells after PBSCT to
test the hypothesis that the transfer of immuneTcellswould reconsti-
tute anti-tumor activity after PBSCT. This primeand post-PBSCT
boostwas performed in 5 patients. In the primingpart of the approach,
all patients received 8 infusions of armed ATC. Approximately 3
weeks after the armed ATC infusions, patients underwent a second
leukopheresis for the generation ofATC, and leukopheresis to collect
stem cells. The expanded ATC from 5 patients at an effector:target
ratio (E/T) of 25:1 exhibited specific cytotoxicity (SC) ranging
from3.7-25.8 (mean5 13.6%)directed at theSK-BR-3breast cancer
cell line. Phenotyping of the cell products from the patients after
armed ATC therapy revealed a mean of 50.2% (25-74 range) CD4+
cells, 30.4% (16.3-51.3) CD8+ cells, 11.6% (4.5-24.3) CD56 +
CD16+ cells, and 29.5% (10.4-41) CD4 +CD25+ cells. Two weeks
after PBSCT, the mean proportions of CD4+ and CD8+ cells were
55.5 and 17.7%, respectively. After HDC and PBSCT, 5 evaluable
patients received multiple infusions with a mean total of 54 billion
ATC (range 16-110 billion). All Cr release assays were done an E:T
of 25:1. Multiple doses of ATC were infused after PBSCT. Pt 1 ex-
hibited SC of 69 and 4.7% at 2 and 4 weeks, respectively, after
PBSCT. Pt 2 exhibited 73, 36, 12, and 10% SC at 0.5, 1, 7, and 18
months. Pt 3 exhibited 26, 21, 14, 37, 24, and 29% SC at 0.5, 1, 2,
3, 6, and 12 months. Pt 4 exhibited 28, 6, and 3% SC at 0.5 and
1 month. Pt 5 exhibited background levels of SC at 0.5 and 1 months
after PBSCT. There was no cytotoxicity directed at Daudi targets.
Several patients exhibited high levels of NK activity directed at
K562 cells early after PBSCT. These data show that transfer of
pre-immunized ATC and T cells in the stem cell product enhance
tumor specific cytotoxicity after HDC and PBSCT for breast cancer.
This pre-boost strategy with targeted T cells may well be applicable
to other tumors and hematologic disorders.31
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Previous, retrospective single institutional and registry analyses
have suggested that pre-existing central nervous system (CNS)
involvement was not a contraindication for AHCT for patients
with non-Hodgkin lymphoma (NHL). We analyzed the outcomes
of 151 (64% male) adult recipients of AHCT with NHL and CNS
involvement identified at any time prior to transplant and compared
them to 4688 AHCT with no CNS lymphoma involvement during
the years 1990-2005. Median follow-up of survivors was 77 months.
Significant baseline differences were noted between the groups.
Patients with pre-existingCNS lymphomamore likely to be youngerat transplant, with lower performance status and higher age adjusted
international prognostic index scores. A greater proportion of
patients in the cohort with CNS involvement had advanced stage
at diagnosis, more aggressive histology and increased number of
extranodal sites. They also had a shorter interval between diagnosis
and transplantation. No significant differences in sex, B or T cell
phenotype, B symptoms at diagnosis, bonemarrow involvement dur-
ing the course of disease, number of prior lines of therapy, condition-
ing regimens, or disease status at transplantation were observed
between cohorts. Cumulative incidences of outcomes and univariate
probabilities of disease-free survival (DFS) and overall survival (OS)
at five years are summarized in table 1. No statistically significant dif-
ferences in non-relapse mortality (NRM), relapse, DFS or OS were
identified between the two groups. Patients withCNS remission (96/
151) at time of AHCT had significantly superior survival compared
with those with active CNSdisease (55/151) at transplant (Table 1B).
Significantly higher relapse rates with an associated diminished DFS
and OS (3 year OS 31%) were found in patients with active disease.
Excellent long-term survival is possible after AHCT in NHL pa-
tients with prior CNS involvement despite adverse baseline prognos-
tic factors. However, best outcomes are in patients who achieve
a CNS remission prior to transplant.Table 1A. Outcomes at 5 Years Post AHCT
Non-CNS CNS P-valueRelapse 57% 61% 0.075
NRM 8% 9% 0.756
OS 49% 42% 0.079
DFS 35% 30% 0.127Table 1B: Pre-transplant CNS Status Impacts Outcomes 3 Years
Post AHCTRemission Active P-valueRelapse 49% 72% \0.001
NRM 5% 9% 0.099
OS 58% 31% \0.001
DFS 46% 19% \0.001GRAFT PROCESSING
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NK cells play a role in reducing relapse in hematological malig-
nancy following AlloSCT (Dunbar et al, Haematologica, 2008). NK
cells limitations include lack of tumor recognition and limited NK
cell numbers (Shereck et al, Ped Bld Can, 2007). To circumvent this,
PB MNCs activation/expansion with genetically engineered K562
cells expressing membrane bound IL-15 and 41BB ligand (K562-
mbIL15-41BBL; Imai/Campana et al, Blood, 2005) have shown to
be increased in number and maintain heterogeneous KIR expression
(Fusaki et al BJH, 2009). CBNK cells can be activated, expanded and
exhibit enhanced cytolytic activity when cultured with antibody/
cytokines (Ayello/Cairo et al,ExpHeme, 2009).We sought to develop
an improved NK expansion system for potential ACI strategies by
comparing CB NK expansion/activation, characterization and NK
cytolytic activation following stimulation with K562-mbIL15-
41BBL (generously supplied by D.Campana, St Jude’s Children’s
Hospital, Memphis, TX). Following 100 Gy irradiation, K562-
mbIL15-41BBL or WTK562 cells were incubated 1:1 with CB
